Search Result
Results for "
Atopic dermatitis
" in MedChemExpress (MCE) Product Catalog:
5
Biochemical Assay Reagents
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-145551
-
|
|
Others
|
Inflammation/Immunology
|
|
Atinvicitinib is a kind of pyrazole compound. Atinvicitinib has the potential for the research of atopic dermatitis (extracted from patent WO2021123094A1) .
|
-
-
- HY-P99301
-
|
Anti-Canine IL31 Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31 monoclonal antibody that can be used for the research of atopic dermatitis (AD) in dogs .
|
-
-
- HY-B1365
-
-
-
- HY-131707
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
LEO 39652 is a dual-soft PDE4 inhibitor with IC50s of 1.2 nM, 1.2 nM, 3.0 nM and 3.8 nM for PDE4A, PDE4B, PDE4C and PDE4D, respectively. LEO 39652 also inhibits TNF-α with an IC50 value of 6.0 nM. LEO 39652 is used for topical research of Atopic dermatitis (AD) .
|
-
-
- HY-169758
-
|
|
JAK
|
Inflammation/Immunology
|
|
CEE321 is a potent pan-JAK inhibitor with an IC50 value of 54 nM. CEE321 potently inhibits biomarkers associated with atopic dermatitis .
|
-
-
- HY-12348
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
LEO 29102 is a potent phosphodiesterase 4 (PDE4) inhibitor with an IC50 value of 5 nM. LEO 29102 inhibits TNFα release. LEO 29102 has the potential for the research of atopic dermatitis .
|
-
-
- HY-159514
-
|
|
NO Synthase
COX
|
Inflammation/Immunology
|
|
Graveolide (Compound 5) is a sesquiterpenoid compound that can be isolated from C. abrotanoides. Graveolide possesses anti-inflammatory activity and can be utilized in the research of atopic dermatitis .
|
-
-
- HY-P991280
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
BMS-981164 is a human IgG1-kappa anti-IL31 monoclonal antibody. The isotype control of BMS-981164 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). BMS-981164 can be used in research related to atopic dermatitis .
|
-
-
- HY-B1365R
-
|
|
Glucocorticoid Receptor
|
Inflammation/Immunology
|
|
Prednicarbate (Standard) is the analytical standard of Prednicarbate. This product is intended for research and analytical applications. Prednicarbate is a topical corticosteroid agent. Prednicarbate can be used for the research of inflammatory skin diseases, such as atopic dermatitis .
|
-
-
- HY-P991258
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis .
|
-
-
- HY-168033
-
-
-
- HY-132847
-
|
SCD-044
|
LPL Receptor
|
Inflammation/Immunology
|
|
Vibozilimod (SCD-044, Example 33) is an orally active and selective S1PR1/EDG1 agonist with an EC50 of less than 1 nM. Vibozilimod has immunomodulatory activity and can reduce the number of lymphocytes. Vibozilimod can be used in the research of inflammatory diseases such as psoriasis and atopic dermatitis .
|
-
-
- HY-100009
-
|
Flufenamic acid butyl ester; Butyl flufenamate
|
COX
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
Ufenamate (Flufenamic acid butyl ester) is an anthranilic acid-based anti-inflammatory drug that can be used in the study of skin diseases such as acute and chronic eczema, contact dermatitis, diaper dermatitis, miliary rashes and atopic dermatitis. Ufenamate has a certain photoprotective effect, reduces the degree of skin erythema and swelling in the photoaging model, downregulates the expression level of COX-2 and can promote the healing of mouse skull defects by secreting BMP2 .
|
-
-
- HY-144683
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
PF-07038124 is a PDE4 inhibitor with an IC50 of 0.5 nM for PDE4B2. PF-07038124 shows inhibitory activities against IL-13, IL4, and IFNγ (IC50=125, 4.1, 1.06 nM, respectively). PF-07038124 can be used for research of atopic dermatitis and plaque psoriasis .
|
-
-
- HY-144683A
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
PF-07038124 hydrochloride is a PDE4 inhibitor with an IC50 of 0.5 nM for PDE4B2. PF-07038124 hydrochloride shows inhibitory activities against IL-13, IL4, and IFNγ (IC50=125, 4.1, 1.06 nM, respectively). PF-07038124 hydrochloride can be used for research of atopic dermatitis and plaque psoriasis .
|
-
-
- HY-172806
-
|
|
PARP
|
Inflammation/Immunology
|
|
PARP14 inhibitor 1 (compound Q22) is a selective PARP14 inhibitor with an IC50 of 5.52 nM. PARP14 inhibitor 1 also exhibits anti-inflammatory effects and a half life of 182 min in mouse liver microsomes. PARP14 inhibitor 1 can be utilized in atopic dermatitis research .
|
-
-
- HY-17010
-
|
SB-275833
|
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Retapamulin (SB-275833) is a topical antibiotic that binds Staphylococcus aureus and E. coli ribosomes with a Kd of 3 nM. Retapamulin can be used in researches of atopic dermatitis and prostate cancer .
|
-
-
- HY-B1616
-
|
|
Glucocorticoid Receptor
|
Inflammation/Immunology
|
|
Clobetasone butyrate is a synthetic glucocorticoid and has topical anti-inflammatory activity especially in skin. Clobetasone butyrate can be used to relieve corticosteroid-responsive dermatoses, including atopic dermatitis and psoriasis .
|
-
-
- HY-P10796
-
|
|
MAPKAPK2 (MK2)
|
Inflammation/Immunology
|
|
YARA peptide, a cell-penetrating peptide, is a MK2 inhibitor. YARA-loaded nanoparticles decreases the levels of inflammatory cytokines (IL-1β, IL-6, and TNF-α) in an ex vivo skin culture model. YARA peptide is promising for research of atopic dermatitis (AD) .
|
-
-
- HY-148074
-
|
RPT193
|
CCR
|
Inflammation/Immunology
|
|
Zelnecirnon (RPT193) is an orally active inhibitor of CCR4, blocks the recruitment of Th2 inflammatory immune cells into inflamed tissues. Zelnecirnon can be used for allergic inflammation in atopic dermatitis, asthma, and other diseases research .
|
-
-
- HY-P99162
-
|
CIM331
|
Interleukin Related
|
Inflammation/Immunology
|
|
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
|
-
-
- HY-P99053
-
-
-
- HY-109085
-
|
OPA-15406
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
Difamilast (OPA-15406) is a topical, selective and nonsteroidal phosphodiesterase-4 (PDE4) inhibitor with particularly efficient inhibition of subtype B (IC50=11.2 nM). Difamilast can be used for the research of mild to moderate atopic dermatitis (AD) .
|
-
-
- HY-P99955
-
-
-
- HY-173601
-
|
|
JAK
|
Inflammation/Immunology
|
|
JAK3-IN-17 is an orally active JAK3 inhibitor (IC50: 14.56 nM). JAK3-IN-17 inhibits the production of IL-2 and IL-6 in a DNCB-induced mouse atopic dermatitis model and exhibits anti-inflammatory activity .
|
-
-
- HY-P99555
-
|
OPN-305
|
Toll-like Receptor (TLR)
MyD88
NOD-like Receptor (NLR)
Tau Protein
Interleukin Related
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .
|
-
-
- HY-P99519
-
|
KPL-716
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) receptor β subunit monoclonal antibody. Vixarelimab inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash .
|
-
-
- HY-109085R
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
Difamilast (Standard) is the analytical standard of Difamilast. This product is intended for research and analytical applications. Difamilast (OPA-15406) is a topical, selective and nonsteroidal phosphodiesterase-4 (PDE4) inhibitor with particularly efficient inhibition of subtype B (IC50=11.2 nM). Difamilast can be used for the research of mild to moderate atopic dermatitis (AD) .
|
-
-
- HY-17010R
-
|
SB-275833 (Standard)
|
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Retapamulin (Standard) is the analytical standard of Retapamulin. This product is intended for research and analytical applications. Retapamulin (SB-275833) is a topical antibiotic that binds Staphylococcus aureus and E. coli ribosomes with a Kd of 3 nM. Retapamulin can be used in researches of atopic dermatitis and prostate cancer[1][2][8].
|
-
-
- HY-B1616R
-
|
|
Glucocorticoid Receptor
|
Inflammation/Immunology
|
|
Clobetasone butyrate (Standard) is the analytical standard of Clobetasone butyrate. This product is intended for research and analytical applications. Clobetasone butyrate is a synthetic glucocorticoid and has topical anti-inflammatory activity especially in skin. Clobetasone butyrate can be used to relieve corticosteroid-responsive dermatoses, including atopic dermatitis and psoriasis .
|
-
-
- HY-13723A
-
|
SDZ-ASM 981 hydrate
|
Phosphatase
|
Inflammation/Immunology
|
|
Pimecrolimus hydrate (SDZ-ASM 981 hydrate) is a potent, nonsteroid and orally active calcineurin inhibitor. Pimecrolimus hydrate shows anti-inflammatory activity. Pimecrolimus hydrate has the potential for the research of atopic dermatitis and oral erosive lichen planus .
|
-
-
- HY-P991162
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tilrekimig is a monoclonal antibody targeting human interleukin 4 (IL-4), interleukin 13 (IL-13), and TSLP (thymic stromal lymphopoietin). Tilrekimig is promising for research of allergic and inflammatory diseases, such as asthma and atopic dermatitis .
|
-
-
- HY-170977
-
|
|
JAK
STAT
|
Inflammation/Immunology
|
|
JAK1/STAT3-IN-1 (compound 4f) is an anti-AD (atopic dermatitis) agent by inhibiting JAK1/STAT3 signaling pathway. JAK1/STAT3-IN-1 inhibits NO generation with an IC50 of 2.17 μM. JAK1/STAT3-IN-1 improves the skin condition of AD-like mice, reduces inflammatory infiltration, inhibits the expressions of p-JAK1/JAK1 and p-STAT3/STAT3, and mitigates the excessive immune response on Calcipotriol (HY-10001) (MC903)-induced AD-like mice .
|
-
-
- HY-169864
-
|
|
LPL Receptor
|
Inflammation/Immunology
|
|
KRO-105714 is the antagonist for sphingosine phosphocholine receptor (SPC Receptor) and sphingosine-1-phosphate receptor 1 (S1P1 Receptor) (IC50=79.2 nM). KRO-105714 inhibits SPC-induced proliferation of NIH3T3 (IC50=5.6 nM), inhibits SPC-induced cell migration (IC50=0.59 μM) and tube formation in HUVECs. KRO-105714 inhibits SPC-induced generation of IL-4 and IL-5, exhibits anti-inflammtory efficacy in mouse atopic dermatitis models .
|
-
-
- HY-106714
-
|
|
Drug Metabolite
|
Inflammation/Immunology
|
|
Clocortolone pivalate is a synthetic glucocorticoid corticosteroid and corticosteroid ester. Clocortolone pivalate is indicated for seborrheic dermatitis, contact dermatitis, atopic dermatitis and psoriasis .
|
-
-
- HY-14939
-
-
-
- HY-A0255
-
|
|
Drug Metabolite
|
Inflammation/Immunology
|
|
Clocortolone is a synthetic glucocorticoid steroid and corticosteroid ester. Clocortolone can be used for seborrheic dermatitis, contact dermatitis, atopic dermatitis, and psoriasis. Clocortolone has local in vivo potency and is not easily absorbed into systemic circulation .
|
-
-
- HY-163498
-
|
|
NOD-like Receptor (NLR)
|
Neurological Disease
Inflammation/Immunology
|
|
NLRP3-IN-37 (Compound 23) is a NLRP3 inhibitor (EC50: 5 nM). NLRP3-IN-37 can be used for NLRP3 related research, such as gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury .
|
-
-
- HY-145351
-
-
-
- HY-P99025
-
|
TNX-650
|
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases .
|
-
-
- HY-106714R
-
|
|
Drug Metabolite
|
Inflammation/Immunology
|
|
Clocortolone pivalate (Standard) is the analytical standard of Clocortolone pivalate. This product is intended for research and analytical applications. Clocortolone pivalate is a synthetic glucocorticoid corticosteroid and corticosteroid ester. Clocortolone pivalate is indicated for seborrheic dermatitis, contact dermatitis, atopic dermatitis and psoriasis .
|
-
-
- HY-18706
-
-
-
- HY-N0184A
-
-
-
- HY-P99018
-
-
-
- HY-A0150
-
|
7a-Chloro-16a-methyl prednisolone
|
Glucocorticoid Receptor
|
Inflammation/Immunology
Cancer
|
|
Alclometasone (7a-Chloro-16a-methyl prednisolone) is a glucocorticoid and inhibits the release of pro-inflammatory mediators from leukocytes. Alclometasone can be used to relieve corticosteroid-responsive dermatoses, including atopic dermatitis, eczema, psoriasis and allergic dermatitis .
|
-
-
- HY-156621
-
|
|
JAK
|
Inflammation/Immunology
|
|
Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases .
|
-
-
- HY-172781
-
|
|
HDAC
|
Inflammation/Immunology
|
|
HDAC6-IN-55 (Compound 15B) is a potent HDAC6 inhibitor and an effective anti-inflammatory agent. HDAC6-IN-55 alleviates atopic dermatitis through anti-inflammatory effects facilitated via TLR4/MAPK, STAT3 and NF-κB pathways. HDAC6-IN-55 alleviates symptoms such as skin edema, dryness, crusting, and peeling in 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis mice .
|
-
-
- HY-NP159
-
|
|
Biochemical Assay Reagents
|
Others
|
|
House Dust Mite Extract, from D.farinae, the most common source of indoor allergens, induces a variety of allergic diseases, including allergic rhinitis, conjunctivitis, allergic asthma, and atopic dermatitis .
|
-
-
- HY-NP159A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
House Dust Mite Extract, from D.pteronyssinus, the most common source of indoor allergens, induces a variety of allergic diseases, including allergic rhinitis, conjunctivitis, allergic asthma, and atopic dermatitis .
|
-
-
- HY-DNP159AF
-
|
|
Biochemical Assay Reagents
|
Others
|
|
House dust mite extract, from D.pteronyssinus (biotinylated), the most common source of indoor allergens, induces a variety of allergic diseases, including allergic rhinitis, conjunctivitis, allergic asthma, and atopic dermatitis .
|
-
- HY-DNP159F
-
|
|
Biochemical Assay Reagents
|
Others
|
|
House dust mite extract, from D.farinae (biotinylated), the most common source of indoor allergens, induces a variety of allergic diseases, including allergic rhinitis, conjunctivitis, allergic asthma, and atopic dermatitis .
|
-
- HY-P991152
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Oturkibart is a humanized immunoglobulin G4-κ monoclonal antibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
|
-
- HY-P991150
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .
|
-
- HY-139095
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
Cipamfylline is a PDE4 inhibitor that can cause PDE4A4 to accumulate in specific areas of the cell through interaction with the ubiquitin scaffolding protein p62. Cipamfylline can be used in the research of atopic dermatitis .
|
-
- HY-158399
-
|
|
STAT
|
Inflammation/Immunology
|
|
STAT6-IN-5 (compound 84) is a STAT6 inhibitor (IC50=0.24 μM), which can be used for the research of inflammatory diseases and allergic diseases (e.g. atopic dermatitis) .
|
-
- HY-N0184AR
-
|
|
Virus Protease
|
Metabolic Disease
Inflammation/Immunology
|
|
Dipotassium glycyrrhizinate (Standard) is the analytical standard of Dipotassium glycyrrhizinate. This product is intended for research and analytical applications. Dipotassium glycyrrhizinate is a HMGB1 inhibitor, inhibits atopic dermatitis-related gene expression with anti-anti-inflammatory activity .
|
-
- HY-17570
-
-
- HY-W099632R
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Dipotassium glycyrrhizinate (Standard) is the analytical standard of Dipotassium glycyrrhizinate. This product is intended for research and analytical applications. Dipotassium glycyrrhizinate is a HMGB1 inhibitor, inhibits atopic dermatitis-related gene expression with anti-anti-inflammatory activity .
|
-
- HY-P9926
-
|
REGN-668; SAR-231893
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis .
|
-
- HY-B0725A
-
|
|
mTOR
PI3K
Akt
|
Neurological Disease
Cancer
|
|
Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant. Doxepin has therapeutic effects in atopic dermatitis，chronic urticarial，can improve cognitive processes， protect central nervous system. Doxepin has also been proposed as a protective factor against oxidative stress .
|
-
- HY-B0248
-
|
|
Glucocorticoid Receptor
Huntingtin
Apoptosis
|
Neurological Disease
Inflammation/Immunology
|
|
Desonide is a non-fluorinated corticosteroid anti-inflammatory agent that acts on the glucocorticoid receptor. Desonide can also specifically bind to the mutant huntingtin protein (mHTT), reducing the level and toxicity of mHTT. Desonide can be used in the research of Huntington's disease and inflammatory diseases such as atopic dermatitis .
|
-
- HY-P99673
-
|
REGN-3500; SAR-440340
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .
|
-
- HY-Z8648
-
|
|
Drug Intermediate
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Δ14-Triamcinolone acetonide is a potential impurity. Triamcinolone acetonide inhibits basic fibroblast growth factor (bFGF) induced proliferation of retinal endothelial cells. Triamcinolone acetonide reduces chondrocyte viability and leads to cartilage destruction. Triamcinolone acetonide can be used in the study of diseases such as atopic dermatitis .
|
-
- HY-B0636
-
|
|
Glucocorticoid Receptor
FGFR
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Triamcinolone acetonide inhibits basic fibroblast growth factor (bFGF) induced proliferation of retinal endothelial cells. Triamcinolone acetonide reduces chondrocyte viability and leads to cartilage destruction. Triamcinolone acetonide activates macrophage with anti-inflammatory characteristics. Triamcinolone acetonide can be used in the study of diseases such as atopic dermatitis .
|
-
- HY-B0248R
-
|
|
Glucocorticoid Receptor
Huntingtin
Apoptosis
|
Neurological Disease
Inflammation/Immunology
|
|
Desonide (Standard) is the analytical standard of Desonide. This product is intended for research and analytical applications. Desonide is a non-fluorinated corticosteroid anti-inflammatory agent that acts on the glucocorticoid receptor. Desonide can also specifically bind to the mutant huntingtin protein (mHTT), reducing the level and toxicity of mHTT. Desonide can be used in the research of Huntington's disease and inflammatory diseases such as atopic dermatitis.
|
-
- HY-17570R
-
|
|
Glucocorticoid Receptor
Interleukin Related
Cytochrome P450
|
Inflammation/Immunology
|
|
Desoximetasone (Standard) is the analytical standard of Desoximetasone (HY-17570). This product is intended for research and analytical applications. Desoximetasone is a corticosteroid and a substrate of cytochrome P450 3A4. Desoximetasone has anti-inflammatory, anti-allergic, and immunosuppressive effects. Desoximetasone can be used in the research of various skin diseases, such as skin allergies, atopic dermatitis, and psoriasis .
|
-
- HY-N4042
-
|
|
PI3K
ERK
|
Inflammation/Immunology
Cancer
|
|
Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone attenuates adipogenesis by binding directly to PI3K and ERK1 in a non-ATP competitive manner. Hirsutenone can be used for the study of obesity .
|
-
- HY-171242
-
|
|
JAK
STAT
|
Others
|
|
LNK01004 is a JAK inhibitor with strong inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50:＜0.51 nM) and TYK2 (IC50: 1.0 nM) . LNK01004 can simultaneously inhibit multiple cytokine-induced p-STAT signaling pathways. LNK01004 can be used in the research of diseases such as atopic dermatitis .
|
-
- HY-W653989
-
|
|
Isotope-Labeled Compounds
|
Others
|
|
Desonide- 13C3 is the 13C labeled isotope of Desonide (HY-B0248). Desonide is a non-fluorinated corticosteroid anti-inflammatory agent that acts on the glucocorticoid receptor. Desonide can also specifically bind to the mutant huntingtin protein (mHTT), reducing the level and toxicity of mHTT. Desonide can be used in the research of Huntington's disease and inflammatory diseases such as atopic dermatitis .
|
-
- HY-156622
-
|
HMC-C-01-A; MBS2320
|
Mitochondrial Metabolism
|
Cancer
|
|
Leramistat (HMC-C-01-A; MBS2320) is a mitochondrial complex 1 inhibitor, involving in cell metabolism immune metabolism regulation. Leramistat also inhibits ATP production in Thp1 human monocytes (IC50: 0.63 μM). Leramistat inhibits atopic dermatitis and other skin diseases autoimmune diseases, inflammatory diseases, cancer; and also inhibits osteoclast mediated disease .
|
-
- HY-W010520
-
|
|
Bacterial
MMP
Apoptosis
Fungal
|
Infection
Inflammation/Immunology
|
|
Methylothiazolinone is a bacterial and fungal inhibitor and preservative, as well as a sensitizer. Methylisothiazolinone can activate matrix metalloproteinases (MMPs) in human bronchial epithelial cells to induce apoptosis and inflammatory response. Methylisothiazolinone can promote the development of atopic dermatitis in mice by disrupting Th2/Th17 related immune responses. Methylisothiazolinone can cause mitochondrial damage in the endothelium of rat cerebral blood vessels .
|
-
- HY-162004
-
|
|
NF-κB
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
NF-κB-IN-14 (compound 5e) significantly inhibits nitric oxide production in LPS-induced macrophages (IC50: 6.4 μM). NF-κB-IN-14 disrupts the TLR4-MyD88 protein interaction, leading to the suppression of the NF-κB signaling pathway suppression. NF-κB-IN-14 reduces ear edema and inflammation in an atopic dermatitis mouse model .
|
-
- HY-103018
-
|
ASN-002
|
JAK
Syk
|
Inflammation/Immunology
Cancer
|
|
Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .
|
-
- HY-103018A
-
|
ASN-002 hydrochloride
|
JAK
Syk
|
Inflammation/Immunology
Cancer
|
|
Gusacitinib (ASN-002) hydrochloride is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib hydrochloride rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib hydrochloride can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .
|
-
- HY-132819
-
|
LY-3411067
|
JAK
|
Others
|
|
Ilunocitinib (compound 27) is a JAK inhibitor (extracted from patent WO2009114512A1) .
|
-
- HY-163731
-
-
- HY-156263
-
|
Luria-Bertani Base
|
Bacterial
Biochemical Assay Reagents
|
Infection
|
|
LB Broth Base, powder (Luria-Bertani Base) is generally used to maintain the growth of E. coli. The composition of 1 liter of LB medium is: 10 g peptone, 5 g yeast extract and 10 g NaCl .
|
-
- HY-W010520R
-
|
|
Reference Standards
Bacterial
MMP
|
Infection
Inflammation/Immunology
|
|
Methylisothiazolinone (Standard) is the analytical standard of Methylisothiazolinone. Methylothiazolinone is a fungicide and preservative, as well as a sensitizer. Methylisothiazolinone can activate matrix metalloproteinases (MMPs) in human bronchial epithelial cells to induce cell apoptosis and inflammatory response. Methylisothiazolinone can promote the development of atopic dermatitis in mice by disrupting Th2/Th17 related immune responses. Methylisothiazolinone can cause mitochondrial damage in the endothelium of rat cerebral blood vessels .
|
-
- HY-176456
-
|
|
PARP
|
Inflammation/Immunology
Cancer
|
|
PARP14 inhibitor 2 (Compound 3) is an orally active and highly selective PARP14 inhibitor with an IC50 value of <30 nM. PARP14 inhibitor 2 inhibits the mono-ADP-ribosyltransferase activity of PARP14 and regulates IFN-γ and IL-4 signaling, reversing protumor macrophage polarization and inhibiting anti-tumor inflammatory responses. PARP14 inhibitor 2 is promising for research of PARP14-related diseases such as tumors, atopic dermatitis and autoimmune diseases .
|
-
- HY-I0021A
-
|
|
Histamine Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Bepotastine tosylate is a selective and orally active second-generation histamine H1 receptor antagonist. Bepotastine tosylate can suppress the expression of nerve growth factor (NGF). Bepotastine tosylate can be used in studies of allergic rhinitis, allergic conjunctivitis and urticaria/pruritus .
|
-
- HY-A0015
-
|
|
Histamine Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Bepotastine besilate is a selective and orally active second-generation histamine H1 receptor antagonist, can suppress the expression of nerve growth factor (NGF). Bepotastine besilate has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research .
|
-
- HY-A0015A
-
|
|
Histamine Receptor
|
Inflammation/Immunology
Endocrinology
|
|
(Rac)-Bepotastine (besilate) is the isomer of Bepotastine (besilate) (HY-A0015), and can be used as an experimental control. Bepotastine besilate is a selective and orally active second-generation histamine H1 receptor antagonist, can suppress the expression of nerve growth factor (NGF). Bepotastine besilate has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research .
|
-
- HY-I0021
-
|
|
Histamine Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Bepotastine is a selective and orally active second-generation histamine H1 receptor antagonist, can suppress the expression of nerve growth factor (NGF). Bepotastine has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research .
|
-
- HY-A0015R
-
|
|
Histamine Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Bepotastine (besilate) (Standard) is the analytical standard of Bepotastine (besilate). This product is intended for research and analytical applications. Bepotastine besilate is a selective and orally active second-generation histamine H1 receptor antagonist, can suppress the expression of nerve growth factor (NGF). Bepotastine besilate has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research .
|
-
- HY-P10415
-
|
hSA(408–423) peptide
|
CXCR
|
Infection
Inflammation/Immunology
Cancer
|
|
EPI-X4 (hSA408–423 peptide) is an antagonist for C-X-C motif chemokine receptor 4 (CXCR4) with IC50 of 8.6 μM. EPI-X4 blocks the CXCL12-mediated signaling, inhibits chemokine-mediated migration and invasion of leukemia cell. EPI-X4 exhibits anti-inflammatory activity in mouse model. EPI-X4 exhibits antiviral activity against CXCR4-tropic HIV with IC50 of 8.6 μM .
|
-
- HY-B0725
-
|
|
Histamine Receptor
Cytochrome P450
|
Neurological Disease
Cancer
|
|
Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2 . Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant .. Doxepin has therapeutic effects in atopic dermatitis，chronic urticarial，can improve cognitive processes， protect central nervous system .. Doxepin has also been proposed as a protective factor against oxidative stress ..
|
-
- HY-N2589
-
|
|
TGF-β Receptor
Collagen
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Isosaponarin is a flavone glycoside isolated from wasabi leaves. Isosaponarin is a P4HA2 enzymatic agonist. Isosaponarin increases collagen synthesis via up-regulated TGF-β type II receptor (TβR-II) and prolyl 4-hydroxylase (P4H) proteins production, promoting skin health and wound healing. Isosaponarin-rich plants exhibit strong antimicrobial, antioxidant, anti-hyaluronidase, antiplatelet, anti-atopic dermatitis, and anti-tumor effects .
|
-
- HY-B0725R
-
|
|
Histamine Receptor
Cytochrome P450
|
Neurological Disease
Cancer
|
|
Doxepin (Hydrochloride) (Standard) is the analytical standard of Doxepin (Hydrochloride). This product is intended for research and analytical applications. Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2 . Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant .. Doxepin has therapeutic effects in atopic dermatitis，chronic urticarial，can improve cognitive processes， protect central nervous system .. Doxepin has also been proposed as a protective factor against oxidative stress ..
|
-
- HY-66019
-
FITC
Maximum Cited Publications
50 Publications Verification
Fluorescein 5-isothiocyanate
|
Fluorescent Dye
|
Inflammation/Immunology
|
|
FITC (Fluorescein Isothiocyanate), is one of the green fluorescein derivatives widely used in biology. FITC has the characteristics of high absorptivity and excellent fluorescence quantum yield. The isothiocyanate group of FITC can be combined with amino, sulfhydryl, imidazole, tyrosyl, carbonyl and other groups on the protein, so as to achieve protein labeling including antibodies and lectins. In addition to its use as a protein marker, FITC can also be used as a fluorescent protein tracer to rapidly identify pathogens by labeling antibodies, or for microsequencing of proteins and peptides (HPLC). The maximum excitation wavelength of FITC is 494 nm. Once excited, it fluoresces yellow-green at a maximum emission wavelength of 520 nm. In addition, FITC is also a hapten that can induce contact hypersensitivity (CHS) and induce an atopic dermatitis model .
|
-
- HY-13723R
-
|
|
Phosphatase
|
Inflammation/Immunology
|
|
Pimecrolimus (Standard) is the analytical standard of Pimecrolimus. This product is intended for research and analytical applications. Pimecrolimus (SDZ-ASM 981) is a potent, nonsteroid and orally active calcineurin inhibitor with a Ki of 117 nM. Pimecrolimus shows anti-inflammatory activity .
|
-
- HY-13723
-
|
SDZ-ASM 981
|
Phosphatase
|
Inflammation/Immunology
|
|
Pimecrolimus (SDZ-ASM 981) is a potent, nonsteroid and orally active calcineurin inhibitor with a Ki of 117 nM. Pimecrolimus shows anti-inflammatory activity .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-66019
-
|
Fluorescein 5-isothiocyanate
|
Fluorescent Dyes/Probes
|
|
FITC (Fluorescein Isothiocyanate), is one of the green fluorescein derivatives widely used in biology. FITC has the characteristics of high absorptivity and excellent fluorescence quantum yield. The isothiocyanate group of FITC can be combined with amino, sulfhydryl, imidazole, tyrosyl, carbonyl and other groups on the protein, so as to achieve protein labeling including antibodies and lectins. In addition to its use as a protein marker, FITC can also be used as a fluorescent protein tracer to rapidly identify pathogens by labeling antibodies, or for microsequencing of proteins and peptides (HPLC). The maximum excitation wavelength of FITC is 494 nm. Once excited, it fluoresces yellow-green at a maximum emission wavelength of 520 nm. In addition, FITC is also a hapten that can induce contact hypersensitivity (CHS) and induce an atopic dermatitis model .
|
| Cat. No. |
Product Name |
Type |
-
- HY-156263
-
|
Luria-Bertani Base
|
Microbial Culture
|
|
LB Broth Base, powder (Luria-Bertani Base) is generally used to maintain the growth of E. coli. The composition of 1 liter of LB medium is: 10 g peptone, 5 g yeast extract and 10 g NaCl .
|
-
- HY-NP159
-
|
|
Native Proteins
|
|
House Dust Mite Extract, from D.farinae, the most common source of indoor allergens, induces a variety of allergic diseases, including allergic rhinitis, conjunctivitis, allergic asthma, and atopic dermatitis .
|
-
- HY-NP159A
-
|
|
Native Proteins
|
|
House Dust Mite Extract, from D.pteronyssinus, the most common source of indoor allergens, induces a variety of allergic diseases, including allergic rhinitis, conjunctivitis, allergic asthma, and atopic dermatitis .
|
-
- HY-DNP159AF
-
|
|
Native Proteins
|
|
House dust mite extract, from D.pteronyssinus (biotinylated), the most common source of indoor allergens, induces a variety of allergic diseases, including allergic rhinitis, conjunctivitis, allergic asthma, and atopic dermatitis .
|
-
- HY-DNP159F
-
|
|
Native Proteins
|
|
House dust mite extract, from D.farinae (biotinylated), the most common source of indoor allergens, induces a variety of allergic diseases, including allergic rhinitis, conjunctivitis, allergic asthma, and atopic dermatitis .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10415
-
|
hSA(408–423) peptide
|
CXCR
|
Infection
Inflammation/Immunology
Cancer
|
|
EPI-X4 (hSA408–423 peptide) is an antagonist for C-X-C motif chemokine receptor 4 (CXCR4) with IC50 of 8.6 μM. EPI-X4 blocks the CXCL12-mediated signaling, inhibits chemokine-mediated migration and invasion of leukemia cell. EPI-X4 exhibits anti-inflammatory activity in mouse model. EPI-X4 exhibits antiviral activity against CXCR4-tropic HIV with IC50 of 8.6 μM .
|
-
- HY-P10796
-
|
|
MAPKAPK2 (MK2)
|
Inflammation/Immunology
|
|
YARA peptide, a cell-penetrating peptide, is a MK2 inhibitor. YARA-loaded nanoparticles decreases the levels of inflammatory cytokines (IL-1β, IL-6, and TNF-α) in an ex vivo skin culture model. YARA peptide is promising for research of atopic dermatitis (AD) .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99301
-
|
Anti-Canine IL31 Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31 monoclonal antibody that can be used for the research of atopic dermatitis (AD) in dogs .
|
-
- HY-P99434
-
|
KY1005; SAR445229
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis .
|
-
- HY-P99162
-
|
CIM331
|
Interleukin Related
|
Inflammation/Immunology
|
|
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
|
-
- HY-P99053
-
-
- HY-P99955
-
-
- HY-P99555
-
|
OPN-305
|
Toll-like Receptor (TLR)
MyD88
NOD-like Receptor (NLR)
Tau Protein
Interleukin Related
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .
|
-
- HY-P99519
-
|
KPL-716
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) receptor β subunit monoclonal antibody. Vixarelimab inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash .
|
-
- HY-P991280
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
BMS-981164 is a human IgG1-kappa anti-IL31 monoclonal antibody. The isotype control of BMS-981164 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). BMS-981164 can be used in research related to atopic dermatitis .
|
-
- HY-P991258
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis .
|
-
- HY-P991162
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tilrekimig is a monoclonal antibody targeting human interleukin 4 (IL-4), interleukin 13 (IL-13), and TSLP (thymic stromal lymphopoietin). Tilrekimig is promising for research of allergic and inflammatory diseases, such as asthma and atopic dermatitis .
|
-
- HY-P99025
-
|
TNX-650
|
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases .
|
-
- HY-P99018
-
-
- HY-P991152
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Oturkibart is a humanized immunoglobulin G4-κ monoclonal antibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
|
-
- HY-P991150
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .
|
-
- HY-P9926
-
|
REGN-668; SAR-231893
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis .
|
-
- HY-P99673
-
|
REGN-3500; SAR-440340
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W653989
-
|
|
|
Desonide- 13C3 is the 13C labeled isotope of Desonide (HY-B0248). Desonide is a non-fluorinated corticosteroid anti-inflammatory agent that acts on the glucocorticoid receptor. Desonide can also specifically bind to the mutant huntingtin protein (mHTT), reducing the level and toxicity of mHTT. Desonide can be used in the research of Huntington's disease and inflammatory diseases such as atopic dermatitis .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
